Navigation Links
MannKind Corporation Reports First Quarter Financial Results
Date:5/5/2008

cessible for approximately 14 days following completion of the call by dialing (866) 457-6651 or (203) 369-1300.

Presenting from the Company will be:

-- Chairman and Chief Executive Officer Alfred Mann

-- President and Chief Operating Officer Hakan Edstrom

-- Corporate Vice President and Chief Financial Officer Matthew Pfeffer

-- Corporate Vice President and Chief Scientific Officer Peter Richardson

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in Phase 3 clinical trials in the United States, Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.

(Tables to follow)

MannKind Corporation

Condensed Statements of Operations

(Unaudited)

(in thousands, except per share amounts)

Three Months Ended March 31,

2008 2007

Revenue $20 $10

Operating expenses:

Research and development 58,445 63,788

General and administrative 15,640 13,550

Total operating expenses 74,085
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. MannKind Corporation Response to Recent Market Events
9. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
10. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
11. MannKind to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... YORK , June 30, 2015  Today, Americord Registry, ... U.S., announced Andrew Horne , a partner at Kirkland ... Board. Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... to Americord,s Advisory Board," says Martin Smithmyer , CEO ... in his legal career that will assist Americord,s growth and ...
(Date:6/30/2015)... FL (PRWEB) , ... June 30, 2015 , ... The ... 7.76% of Cryo-Cell’s currently outstanding common shares (including shares of unvested restricted stock). On ... offer, the last sale price of Cryo-Cell’s shares reported on the OTCBB was $2.29 ...
(Date:6/30/2015)... June 30, 2015 /PRNewswire/ - RepliCel Life Sciences ... regenerative medicine company focused on the development of ... in its Phase 1/2 clinical trial of RCT-01, ... Achilles tendinosis, has been enrolled and their tissue ... injections. RCT-01 is comprised of non-bulbar dermal sheath ...
(Date:6/30/2015)... ... June 30, 2015 , ... Cannavoices , ... an unprecedented digital video and broadcast initiative. Produced by filmmakers, the multi-platform initiative ... of legal medical cannabis stories ever assembled. , Cannavoices profiles Advocates, Patients, ...
Breaking Biology Technology:Americord Registry Announces Andrew Horne as Advisory Board Member 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3
... The new Pearl(TM) In Vivo,Imaging System for small ... results in less than 30 seconds. The Pearl ... Dyes, the proven performers,for NIR imaging at 700 ... acquired in 30 seconds," says,Jeff Harford, LI-COR product ...
... Calif., June 12 GenVault Corporation today,announces Paul ... Systems Inc.,has joined its Board of Directors. Mr. ... diagnostic imaging with GE Healthcare where he held,leadership ... on this substantial background in diagnostics and the ...
... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced ... Directors., "We are pleased to welcome Mr. Johnson ... Directors," said Barry D. Quart, PharmD, Ardea,Biosciences, President and ... he will chair our Audit Committee. We look,forward to ...
Cached Biology Technology:LI-COR Biosciences Introduces Near-Infrared Small Animal Imager 2Paul J. Mirabella, President and CEO of Naviscan PET Systems Inc., Joins GenVault's Board of Directors 2Craig Johnson Joins Ardea Biosciences' Board of Directors 2Craig Johnson Joins Ardea Biosciences' Board of Directors 3
(Date:6/30/2015)... To bolster its efforts and commitment to fighting cyber fraud, ... of two new team members. Dimitri ... Raviv will act as head of strategic alliances. These ... the most secure solutions for the enterprise market. ... a provider of security and management products, which was acquired ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:6/25/2015)... June 25, 2015 According ... Type (Swipe & Area), Technology, Material (Optical Prism, ... Commercial Security & Others) & Geography - Global ... the said market is expected to reach $14,500.07 ... Browse 76 market Tables and ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... versatile strawberry has been introduced for home gardeners. ,Roseberry, ... addition to gardens. The strawberry features attractive pink blooms ... it produces flowers and fruits on stolons before they ... when planted as groundcover. ,Roseberry, premiered in HortScience ...
... Geoffroy Berthelot and Stephane Len, both researchers at the ... at INSEP, Paris, France), have published their findings in ... Aging Association, describing the evolution of performances in elite ... the epidemiological approaches developed by the laboratory, and suggests ...
... Spanish . Studies by U.S. Department ... Escherichia coli pathogens in surface waters could result ... sediments. Most E. coli strains don,t cause ... managers to estimate fecal contamination. These findings, which can ...
Cached Biology News:Evolution of sport performances follows a physiological law 2E. coli can survive in streambed sediments for months 2
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Rabbit polyclonal to MAP3K12 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH from the C-terminal region of human MAP3K12 Entrez Gene ID: 7786 Swiss ...
Amino-acids and Derivatives Rabbit Anti-conjugated L-isoleucine Polyclonal Antibody...
Biology Products: